Liftstream is an executive search recruitment company in the life sciences sector
Voyager Therapeutics Appoints Jane Pritchett Henderson as Chief Financial Officer
Voyager Therapeutics, a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced the appointment of Jane Pritchett Henderson as senior vice president and chief financial officer effective January 1, 2017. Ms. Henderson brings more than 28 years of life sciences industry and banking experience and leadership to her new role.
Immatics Nominates Katina Dorton as CFO
Immatics Biotechnologies, a biopharmaceutical company focused on cancer immunotherapy, has appointed Katina Dorton as CFO. “Dorton’s experience working with innovative life sciences companies and strong track record leading corporate transactions and managing financial operations makes her an excellent addition to the Immatics senior management team,” commented Immatics Chairman Peter Chambré.
Codiak BioSciences Begins to Appoint Executives to Leadership Team
Codiak BioSciences, a venture-backed start-up in Cambridge, Mass, has appointed Ariel Jasie as Chief Business Officer, Linda Bain as CFO and Konstantin Konstantinov as Senior Vice President.
Pharming snares ex-Karolinska Development CFO
Pharming Group NV (EURONEXT: PHARM) proposed the election of Mr Robin Wright as the Company’s new Chief Financial Officer (CFO) and member of the Management Board at an Extraordinary General Meeting (“EGM”) of shareholders, to be held on Wednesday 28 October 2015 at 14:00 hrs CET.
Editas adds CFO and $120m in Series B round
Editas Medicine, a leading genome editing company, today announced that it has raised $120 million in a highly oversubscribed Series B private financing. The financing assembles a broad syndicate of leading public and private investors who underpin many of the most innovative biopharmaceutical and technology companies.
Dimension Therapeutics Diversifies Leadership with Management and Board Appointment
Dimension Therapeutics, a leading rare disease company advancing novel, liver-directed treatments for diverse genetic disorders has announced that it has expanded its Board of Directors with the elections of Georges Gemayel, Ph.D., former Executive Vice President of Genzyme Corporation, and Arlene M. Morris, former CEO of Syndax Pharmaceuticals. Dimension also announced that Donald J. Hayden, Jr., is leaving his position as a member of the Company’s Board of Directors.
BrainStorm recruits new CFO
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that it has appointed Yoram Bibring as Chief Financial Officer, effective July 30, 2015. Mr. Bibring will be responsible for all corporate finance and accounting activities for BrainStorm, and will replace Ms. Alla Patlis, the Company’s current interim CFO, who will resume her duties as Controller of the Company.
Executive and Board Director Appointments in Oncology and Rare Diseases
Third Rock Ventures portfolio company, Voyager Therapeutics, a gene therapy player in the field of CNS based out of Cambridge, Mass. have appointed Michael Higgins to the Board of Directors. Mr. Higgins is an experienced biotechnology executive and is currently an entrepreneur-in-residence at Polaris Partners. Previously, he served as chief operating officer and chief financial officer at Ironwood Pharmaceuticals, Inc. from 2003 through 2014. In 2014, Mr. Higgins was named the Boston Business Journal’s CFO of the Year. Mr. Higgins worked at Genzyme Corporation, with which Voyager Therapeutics now has a partnership, from 1997 through 2003 in a variety of leadership roles, including vice president of corporate finance and vice president of business development. While at Genzyme, he was involved with multiple business units, including Cell Therapy, Gene Therapy and Orphan Diseases.
OXiGENE Appoints Matthew M. Loar as Chief Financial Officer
OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel therapies for treatment of cancer, announced that Matthew M. Loar has been appointed Chief Financial Officer. Mr. Loar is a seasoned financial executive with over 20 years of financial and accounting experience in both public and private companies in the biopharmaceutical industry.